NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022

Natalie S. Callander(University of Wisconsin Carbone Cancer Center), Muhamed Baljević(Susan Thompson Buffett Foundation), Kehinde Adekola(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Larry D. Anderson(Southwestern Medical Center), Erica Campagnaro(University of Michigan), Jorge J. Castillo(Massachusetts General Hospital), Caitlin Costello(Moore College of Art and Design), Srinivas Devarakonda(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Noura Elsedawy(St. Jude Children's Research Hospital), Matthew Faiman(Cleveland Clinic), Alfred L. Garfall(UPMC Hillman Cancer Center), Kelly Godby(University of Colorado Cancer Center), Jens Hillengaß(Roswell Park Comprehensive Cancer Center), Leona Holmberg(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Myo Htut(City Of Hope National Medical Center), Carol Ann Huff(Sidney Kimmel Comprehensive Cancer Center), Malin Hultcrantz(Memorial Sloan Kettering Cancer Center), Yubin Kang(Cancer Institute (WIA)), Sarah Larson(University of Colorado Cancer Center), Michaela Liedtke(Cancer Institute (WIA)), Thomas G. Martin(UCSF Helen Diller Family Comprehensive Cancer Center), James Omel, Douglas W. Sborov(University of Utah), Kenneth H. Shain(Moffitt Cancer Center), Keith Stockerl‐Goldstein(Barnes-Jewish Hospital), Donna Weber(The University of Texas MD Anderson Cancer Center), Ryan A. Berardi(Pancreatic Cancer Action Network), Rashmi Kumar(Pancreatic Cancer Action Network), Shaji Kumar(Cancer Clinic)
Journal of the National Comprehensive Cancer Network
January 1, 2022
Cited by 209

Abstract

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.


Related Papers

No related papers found

Powered by citation graph analysis